Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PNT

POINT Biopharma Global Inc

Dec 08 • 04:00PM ET

14.06

Dollar change +0.11
Percentage change 0.79	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	15.72	EPS (ttm)	0.89	Insider Own	17.83%	Shs Outstand	105.65M	Perf Week	1.88%
Market Cap	1.50B	Forward P/E	-	EPS next Y	-1.07	Insider Trans	0.00%	Shs Float	87.57M	Perf Month	7.99%
Income	96.55M	PEG	-	EPS next Q	-0.28	Inst Own	61.60%	Short Float / Ratio	4.19% / 1.34	Perf Quarter	79.11%
Sales	243.69M	P/S	6.15	EPS this Y	-189.91%	Inst Trans	25.38%	Short Interest	3.67M	Perf Half Y	37.30%
Book/sh	4.01	P/B	3.51	EPS next Y	-16.14%	ROA	24.04%	Target Price	14.31	Perf Year	109.85%
Cash/sh	3.18	P/C	4.42	EPS next 5Y	-	ROE	26.33%	52W Range	6.39 - 14.00	Perf YTD	92.87%
Dividend	-	P/FCF	16.16	EPS past 5Y	-	ROI	22.30%	52W High	0.43%	Beta	-0.00
Dividend %	-	Quick Ratio	9.14	Sales past 5Y	0.00%	Gross Margin	98.93%	52W Low	120.03%	ATR	0.32
Employees	129	Current Ratio	9.14	Sales Q/Q	-	Oper. Margin	44.23%	RSI (14)	74.14	Volatility	2.15% 2.59%
Optionable	Yes	Debt/Eq	0.03	EPS Q/Q	9.89%	Profit Margin	39.62%	Rel Volume	0.57	Prev Close	13.95
Shortable	Yes	LT Debt/Eq	0.02	Earnings	Nov 13 BMO	Payout	0.00%	Avg Volume	2.75M	Price	14.06
Recom	2.60	SMA20	3.37%	SMA50	10.90%	SMA200	48.77%	Volume	1,566,647	Change	0.79%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-20-23	Resumed	Jefferies	Buy	$12 → $14
Dec-14-22	Initiated	Raymond James	Outperform	$10
Nov-30-22	Initiated	SVB Leerink	Outperform	$14
Oct-11-22	Initiated	Oppenheimer	Outperform	$20
Sep-16-22	Initiated	Truist	Buy	$22
Sep-14-22	Initiated	Berenberg	Buy	$20
Aug-16-22	Initiated	Guggenheim	Buy	$20
Jul-06-22	Initiated	William Blair	Outperform
May-26-22	Upgrade	Jefferies	Hold → Buy	$7 → $20
Jul-29-21	Initiated	Cowen	Outperform
Jul-27-21	Initiated	Jefferies	Hold	$8
Jul-26-21	Initiated	Piper Sandler	Overweight	$17

Show Previous Ratings

Dec-05-23 01:11PM	POINT Biopharma Global (PNT) News: Johnson Fistel Investigates Proposed Sale; Is $12.50 a Fair Price? (GlobeNewswire)
Dec-04-23 06:45AM	Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023 (PR Newswire)
Nov-29-23 10:45AM	Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment (PR Newswire)
Nov-22-23 10:17AM	POINT Biopharma Global (PNT) News: Johnson Fistel Investigates Proposed Sale; Is $12.50 a Fair Price? (GlobeNewswire)
Nov-17-23 06:45AM	Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023 (PR Newswire)
04:33PM	Loading…
Nov-14-23 04:33PM	Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma (PR Newswire)
10:15AM	POINT Biopharma Global (PNT) News: Johnson Fistel Investigates Proposed Sale; Is $12.50 a Fair Price? (GlobeNewswire)
Nov-13-23 07:30AM	POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-08-23 04:56PM	Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma (PR Newswire)
Oct-26-23 12:29PM	Moore Kuehn Encourages PNT, VERY, MRTX, and ORTX Investors to Contact Law Firm (PR Newswire)
Oct-13-23 02:56PM	Moore Kuehn Encourages TWNK, LVOX, ACER, and PNT Investors to Contact Law Firm (PR Newswire)
Oct-10-23 10:22AM	Moore Kuehn Encourages VERY, PNT, LAB, and LVOX Investors to Contact Law Firm (GlobeNewswire)
Oct-03-23 04:22PM	Cruise lines, spinoff slumps, Eli Lilly-Point deal: Trending Stocks (Yahoo Finance Video) +84.89%
11:39AM	Eli Lilly Buys POINT Biopharma to Boost Its Cancer-Fighting Therapies (Investopedia)
11:07AM	Stocks to Watch Tuesday: Netflix, Alibaba, Point Biopharma, McCormick, Airbnb (The Wall Street Journal)
06:45AM	Loading…
06:45AM	Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies (PR Newswire)
Sep-18-23 08:00AM	POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands (GlobeNewswire)
Aug-14-23 07:30AM	POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Jul-31-23 09:00AM	ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177 (GlobeNewswire)
Jun-26-23 07:45AM	POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands (GlobeNewswire) -10.28%
07:30AM	POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMIs Annual Congress (GlobeNewswire)
Jun-12-23 08:00AM	POINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of Directors (GlobeNewswire)
Jun-07-23 07:00AM	POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023 (GlobeNewswire)
May-25-23 08:30AM	POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO (GlobeNewswire)
May-15-23 07:35AM	POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer (GlobeNewswire) +9.83%
07:30AM	POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-24-23 07:30AM	Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer (GlobeNewswire)
Apr-04-23 08:00AM	Eckert & Ziegler to Supply POINT Biopharma with Actinium-225 (GlobeNewswire)
Mar-27-23 08:00AM	POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights (GlobeNewswire)
Mar-07-23 07:45AM	POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (GlobeNewswire)
08:30AM	Loading…
Feb-02-23 08:30AM	POINT Biopharma to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-12-23 08:30AM	POINT Biopharma Completes Randomization in PNT2002s Phase 3 SPLASH Trial (GlobeNewswire) +6.06%
Dec-20-22 08:30AM	POINT Biopharma Announces Closing of Agreements with Lantheus Holdings (GlobeNewswire)
Nov-29-22 07:30AM	POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy (GlobeNewswire)
Nov-14-22 07:15AM	POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings (GlobeNewswire) -37.42%
07:00AM	Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 (GlobeNewswire)
Oct-17-22 08:30AM	POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, a Next-Generation PSMA Ligand, at EANMs Annual Congress (GlobeNewswire)
Sep-16-22 04:30PM	POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock (GlobeNewswire) +6.64%
Sep-13-22 09:47PM	POINT Biopharma Prices Public Offering of Common Stock (GlobeNewswire)
04:05PM	POINT Biopharma Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Sep-10-22 03:05AM	POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022 (GlobeNewswire)
Sep-04-22 06:10PM	POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial (GlobeNewswire)
Aug-18-22 04:30PM	POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial (GlobeNewswire) +5.47%
Aug-12-22 08:30AM	POINT Biopharma Reports Second Quarter 2022 Financial Results and Provides Business Highlights (GlobeNewswire) +8.88%
Aug-08-22 08:30AM	POINT Biopharma to Host Investor Education Event, Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm, on August 18, 2022 (GlobeNewswire) +6.25%
Jul-06-22 08:30AM	POINT Biopharma to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.56%
Jun-21-22 08:30AM	POINT Biopharma announces appointment of Chris Horvath as EVP, Commercial (GlobeNewswire)
May-19-22 05:30PM	POINT Biopharma to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.45%
May-16-22 08:30AM	POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP- Targeted Clinical Program (GlobeNewswire)
May-13-22 08:30AM	POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
May-05-22 09:15AM	POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial (GlobeNewswire)
Apr-26-22 08:30AM	First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial (GlobeNewswire)
Apr-11-22 04:30PM	POINT Biopharma to Present on its Pan-Cancer FAP-Alpha Targeted Program at the AACR Annual Meeting (GlobeNewswire)
Mar-30-22 12:40PM	What Kind Of Investors Own Most Of POINT Biopharma Global Inc. (NASDAQ:PNT)? (Simply Wall St.)
Mar-25-22 08:30AM	POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-22-22 08:30AM	POINT Biopharma Confirms No Delays to SPLASH Trial Due to Recent Global Lutetium Supply Interruption (GlobeNewswire)
Mar-15-22 04:30PM	POINT Biopharma to Host Dosimetry Investor Education Event on March 29, 2022 (GlobeNewswire) +6.78%
Feb-25-22 09:00AM	POINT Biopharma Announces Abstract Publication of Dosimetry Data Findings from the Lead-In Cohort of the SPLASH trial in mCRPC at the 2022 SNMMI Mid-Winter & ACNM Annual Meeting (GlobeNewswire)
Feb-17-22 08:30AM	POINT Biopharma to Participate in Upcoming Virtual Investor Conferences (GlobeNewswire)
Feb-14-22 08:30AM	POINT Biopharma Provides Early-Stage Program Updates (GlobeNewswire)
Feb-01-22 08:30AM	POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs (GlobeNewswire)
Jan-24-22 05:38PM	Baskin Financial Services Inc. Buys CoStar Group Inc, Watsco Inc, Tricon Residential Inc, Sells ... (GuruFocus.com)
Jan-04-22 08:30AM	POINT Biopharma Adds Senior BD Expertise with Appointment of Dr. Matthew Vincent as SVP, Business Development (GlobeNewswire)
Dec-01-21 08:30AM	POINT Biopharma adds a COO, Further Strengthens Leadership Team, and Announces Additional Board and Leadership Changes (GlobeNewswire) +7.93%
Nov-24-21 08:30AM	POINT Biopharma Licenses Innovative Lu-177 Production Technology from SCK CEN (Belgian Nuclear Research Center) (GlobeNewswire)
Nov-22-21 08:30AM	POINT Biopharma to Host Virtual Education Event on December 6, 2021 (GlobeNewswire)
Nov-12-21 08:30AM	POINT Biopharma Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-21 08:30AM	POINT Biopharma and IONETIX Announce Ac-225 Supply Agreement (GlobeNewswire)
Oct-29-21 08:30AM	POINT Biopharma and Kinectrics Announce Yb-176 Supply Agreement Enabling North American Production of n.c.a. Lu-177 (GlobeNewswire)
Sep-28-21 08:00AM	POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor (GlobeNewswire)
Sep-23-21 08:00AM	POINT Biopharma Announces Initiation of Randomization for its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC (GlobeNewswire) -8.88%
Sep-14-21 07:33AM	Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV 01- (Rosopatamab-225Ac) in combination with PNT2002 for Progressive Metastatic Castration-Resistant Prostate Cancer (PR Newswire)
Sep-08-21 08:30AM	NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225 (Business Wire)
Sep-07-21 08:00AM	POINT Biopharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-13-21 07:06AM	POINT Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire) -7.40%
Aug-10-21 04:01PM	POINT Biopharma Announces Early Completion of enrollment and initial dosing in the Lead-In of its Phase 3 SPLASH study of PNT2002 for mCRPC (GlobeNewswire)

POINT Biopharma Global, Inc. is a radiopharmaceutical company. It engages in the business of building a platform for the clinical development and commercialization of radioligands that fight cancer. The company was founded by Joe McCann and Neil E. Fleshner on April 15, 2020 and is headquartered in Indianapolis, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HOGUE GERALD L.	Director	Mar 21	Option Exercise	6.97	17,936	125,014	21,596	Mar 23 08:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PNT

POINT Biopharma Global Inc

Upgrade your FINVIZ experience